Next Article in Journal
Preparation and Characterization of Epoxy Resin Filled with Ti3C2Tx MXene Nanosheets with Excellent Electric Conductivity
Next Article in Special Issue
Immunological and Toxicological Considerations for the Design of Liposomes
Previous Article in Journal
Surfactant-Free Synthesis of Nb2O5 Nanoparticles Anchored Graphene Nanocomposites with Enhanced Electrochemical Performance for Supercapacitor Electrodes
Previous Article in Special Issue
Effects of Metal Oxide Nanoparticles on Toll-Like Receptor mRNAs in Human Monocytes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nanomaterials
Volume 10
Issue 1
10.3390/nano10010161
Review Report
nanomaterials-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma

Nanomaterials 2020, 10(1), 161; https://doi.org/10.3390/nano10010161
by Debbie K. Ledezma 1,2, Preethi B. Balakrishnan 2, Juliana Cano-Mejia 2, Elizabeth E. Sweeney 2, Melissa Hadley 2, Catherine M. Bollard 1,2,3, Alejandro Villagra 2 and Rohan Fernandes 1,2,4,*
Reviewer 1:
Aida Martin Galan
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Nanomaterials 2020, 10(1), 161; https://doi.org/10.3390/nano10010161
Submission received: 8 December 2019 / Revised: 11 January 2020 / Accepted: 15 January 2020 / Published: 17 January 2020
(This article belongs to the Special Issue Immune Responses to Nanomaterials for Biomedical Applications)

Round 1

Reviewer 1 Report

The manuscript shows a detailed in-vivo and in-vitro study using PLGA particles that encapsulates FDA approved photothermal and epigenetic agents for melanoma therapy.

I recommend to accept the paper after minor revisions I expect the article to make a significant contribution to the literature.

1) The paper includes many abbreviations and sometimes it overwhelms the reader. Simplify the number or make it simple to quickly understand which therapy was used. Use longer and easy nomenclature:

free ICG, ICG-PLGA, NextA-PLGA, ICG-Next-PLGA, free ICG-NextA, free NextA, PLGA.

NPs and NAPs can be misinterpreted.

2) Include a final table in the discussion section to follow better the comparison with previous papers.

3) Include error bars in the graphs/data and units for all axis, example Figure 5 c-e.

4) Explain >100% in no tumor for table 2.

5) Include some further discussion about the % drug/agent that is loaded/unloaded from the PLGAs versus free-drug to better understand the behavior in the tumor.

 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

The paper by Ledezma et al. suggests the use of a combined approach to the in situ PPT treatment of melanoma using PLGA nanoparticles loaded with both a PPT agent and an epigenetic drug. Nanoparticles production and characterization and in vitro and in vivo experiments are well designed and results are sounded. However, in order to understand the value of a such novel approach,  I would have also used a lethal PPT conduction as a positive control.

 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 3 Report

The comments are attached below as a pdf file.

Comments for author File: Comments.pdf

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Round 2

Reviewer 3 Report

I accept the changes provided and recommend the current version of the manuscript for publication in Nanomaterials.

Back to TopTop